Concepta PLC

Written by Huub Verschueren

Concepta is a small UK-based company that focuses on the development and commercialization of its medical diagnostic device MyLotus. The device, a consumer good, has been developed to improve the probability of conception for women with unexplained infertility (not pregnant after 12+ months trying).

In this initiated coverage on Concepta, we believe we have touched upon the most important value drivers for the company in the nearby future. The single most important value driver is Concepta’s ability to land a commercialization partnership for its device in the EU. This assumed partnership justifies our current fair share price estimate of 23.85p which represents a premium of close to 20% on top of the current share price.


Latest Research